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ABSTRACT 
Disturbed homeostasis of glucose and lipid metabolism are dominant features of the so-called metabolic syn-
drome (MetS) and can increase the risk for the development of type 2 diabetes (T2D), a severe metabolic dis-
ease. T2D prevalence increases with age. The aryl hydrocarbon receptor (AHR) is a sensor of small molecules 
including dietary components. AHR has been identified as potential regulator of glucose homeostasis and lipid 
metabolism. Epidemiologically, exposure to xenobiotic AHR ligands such as polycyclic aromatic hydrocarbons 
is linked to T2D. We assess here the potential role of the AHR in disturbances of glucose and lipid metabolism 
in young (age 2-5 months) and old (age > 1,5 years) AHR-deficient (AHR KO) mice. Fasted young wildtype 
(WT) and AHR-KO mice displayed similar blood glucose kinetics after challenge with intra-peritoneal glucose 
injection. However, old AHR-KO mice showed lower tolerance than WT to i.p. administered glucose, i.e. glu-
cose levels rose higher and returned more slowly to normal levels. Old mice had overall higher insulin levels 
than young mice, and old AHR-KO had a somewhat disturbed insulin kinetic in the serum after glucose chal-
lenge. Surprisingly, young AHR-KO mice had significantly lower triglycerides, cholesterol, high density lipo-
protein values than WT, i.e., a dyslipidemic profile. With ageing, AHR-KO and WT mice did not differ in these 
lipid levels, except for slightly reduced levels of triglycerides and cholesterol. In conclusion, our findings in 
AHR KO mice suggest that AHR expression is relevant for the maintenance of glucose and lipid homeostasis in 
old mice.  
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INTRODUCTION  
Diabetes mellitus is characterized by 
high blood glucose levels, caused either by 
lack of insulin due to autoimmune destruc-
tion of the insulin secreting cells in the pan-
creas (Type 1 diabetes), or by reduced insu-
lin sensitivity of insulin responsive tissues, 
so-called insulin-resistance (Type 2 diabetes, 
T2D) or by a combination of both disorders 
(ADA, 2014) In either condition, regulation 
of glucose homeostasis is impaired. Long 
term consequences of untreated T2D are car-
diovascular damage, kidney complications, 
blindness, and impaired wound healing. 
T2D, by far the most frequent form of diabe-
tes affects more than 300 Million people 
worldwide, develops with age, and is often 
associated with changes in glucose and lipid 
metabolism, obesity, and/or hypertension. 
Detection of some or all of these parameters 
is frequently referred to as the “metabolic 
syndrome”, and by some considered a warn-
ing sign of developing T2D (Prasad et al., 
2012). The factors which can contribute to 
the broad inter-individual variance and con-
tribution of these changes in metabolic pa-
rameters are not clear. However, age is a ma-
jor risk factor for the development of dis-
turbances of glucose and lipid metabolism.  
Recent epidemiological studies have re-
vealed a link between environmental factors, 
especially traffic-related air pollution, and 
diabetes or metabolic syndrome (Hutcheson 
and Rocic, 2012; Kramer et al., 2010; Raja-
gopalan and Brook, 2012). Moreover, persis-
tent organic pollutants and polycyclic aro-
matic hydrocarbons (PAH), notably 2,3,7,8-
tetrachlorodibeno-p-dioxin (TCDD), are as-
sociated with insulin resistance and T2D. A 
significant increase in T2D incidence was 
observed in 2,3,7,8-TCDD-exposed indivi-
duals in the Yusho accident in Japan, in Vi-
etnam Veterans, and in the victims of the 
Seveso-incident 1976 in Italy (Bertazzi et al., 
2001; Kashima et al., 2015; Warner et al., 
2013). The mechanisms are not clear, but 
possibly inflammatory cytokines such as 
TNF contribute to a lower availability of 
the glucose transporter Glut4 in muscle cells. 
(Fujiyoshi et al., 2006). 
The transcription factor AHR, a member 
of an evolutionarily old protein family, is a 
sensor of small chemicals, including natural 
dietary substances, but also man-made PAHs 
such as TCDD and other environmental pol-
lutants. Binding of AHR to these chemicals 
(called “ligands”) triggers adaptive and cell-
specific intracellular responses. AHR resides 
in the cytoplasm complexed with accessory 
molecules (hsp90 and others). Binding of 
ligands changes the conformation of AHR 
and exposes an importin binding site. AHR 
moves into the nucleus where it sheds the 
accessory proteins and binds to partner mol-
ecule ARNT; together they form a functional 
transcription factor. AHR/ARNT binds to 
short promoter elements called “dioxin re-
sponsive elements”, DRE. Numerous genes 
have DRE sites in their promoters. Histori-
cally, AHR was first recognized as the ma-
ster regulator of a battery of xenobiotic me-
tabolizing enzymes, such as CYP4501A1. 
More recent research demonstrated its in-
volvement in the modulation of stress genes 
and genes of gluconeogenesis and lipid me-
tabolism (Dere et al., 2011; Diani-Moore et 
al., 2010; Minami et al., 2008). AHR is an 
important signaling molecule for immune re-
sponses, notably for the balance between in-
flammatory and regulatory T cell response, 
and for differentiation programs of innate 
immune cells (Kiss et al., 2011; Lee et al., 
2011; Nguyen et al., 2013; Stockinger et al., 
2014). Both persistent and strong activation 
by non-degradable molecules such as TCDD 
and complete lack of AHR impairs important 
functions (Esser C, 2014). By now, it is rec-
ognized that there is a healthy level for AHR 
activated by physiological ligands.  
Exposure to the high affinity AHR ligand 
TCDD has long been known to decrease se-
rum glucose and triglyceride concentrations, 
and to cause progressive weight loss and 
deadly cachexia at high doses (30-day LD50 
for C57BL/6 mice 182 µg/kg body weight) 
(Chapman and Schiller, 1985; Poland and 
Knutson, 1982). More recently, genome 
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wide-expression analyses identified gene 
networks involved in lipid metabolism as 
changed by TCDD exposure in mice and 
rats. A single oral dose of 30 µg/kg TCDD 
resulted in gene responses involving steroid, 
lipid and carbohydrate metabolism in hepatic 
tissue of mice (Nault et al., 2013). In murine 
adipose tissue, expression of inflammatory 
genes dominated upon TCDD treatment 
compared to controls (Kim et al., 2012). 
Moreover, epidemiological research suggests 
that exposure to pollution containing poten-
tial AHR-ligands contribute to inflammation, 
obesity and cardiovascular disease 
(Consonni et al., 2008; Cranmer et al., 2000; 
Kramer et al., 2010). It remains unclear to 
what extent the systemic lack of AHR – as 
opposed to its activation by TCDD – affects 
lipid and glucose metabolism, or parameters 
of metabolic syndrome, especially when an-
imals age. To address this gap, we analyzed 
key parameters of glucose and lipid metabo-
lism in young and old AHR-deficient mice.  
 
MATERIAL AND METHODS 
Mice 
AHR-deficient mice (Schmidt et al., 
1996) and C57BL/6 wild-type mice, or lit-
termates as controls were used. Mice re-
ceived standard chow and water ad libitum, 
and lived on a 12/12 light-dark cycle. Exper-
iments were done with permission, in ac-
cordance with relevant German animal wel-
fare laws.  
 
Measurement of glucose and glucose  
tolerance  
For glucose tolerance tests (GTT), mice 
were fasted for 15 hours. Mice were injected 
i.p. with a 20 % glucose solution in saline 
giving 2 g/kg body weight. Blood glucose 
was measured at 0, 15, 30, 60, 90, and 120 
min from a drop of tail vein blood, using l 
Freestyle lite glucometer (Abbot, Alameda, 
CA, USA).  
 
Determination of serum insulin levels 
Insulin was measured from sera using a 
solid phase two-site enzyme immunoassay 
based on the sandwich technique (Ultrasensi-
tive Mouse Insulin ELISA; Mercodia, Upp-
sala, Sweden). In brief, 5 µl of the serum 
samples were added to each well of a 96 well 
plate pre-coated with an antibody against a 
distinct antigenic determinant of the insulin 
molecule. A peroxidase-conjugated antibody 
directed against a separate insulin epitope 
was added. After 6 h of incubation at room 
temperature, TMB as substrate was added 
for 15 min. Thereafter, stop solution was 
added, the O.D. of the resulting solution was 
measured in a multichannel photometer at 
450 nm, and the insulin concentrations were 
quantified from a standard curve.  
 
TG, HDL, LDL and cholesterin  
measurements  
Serum was obtained by centrifugation at 
4 °C and 3000 x g and stored at -20 °C. Se-
rum levels of triglyceride were analyzed by 
colorimetry using ABX Pentra reagent (ABX 
Diagnostics Montpellier, France). The de-
termination of cholesterol, HDL and LDL 
was done by photometry using reagents from 
DIALAB (Wiener Neudorf, Austria). To 
measure the serum lipids a chemistry analyz-
er (Roche Hitachi Cobas Mira Plus) was 
used. Concentrations of VLDL were calcu-
lated by subtraction of the subunits LDL and 
HDL from total cholesterol. 
 
Statistical analysis 
Data were analyzed with GraphPad 
Prism® software. Data are expressed as mean 
± SD and analyzed using unpaired two tailed 
Student t test. A significant difference was 
considered when P < 0.05.  
 
RESULTS 
Oral glucose tolerance is impaired in AHR-
KO mice 
We tested whether there is a difference in 
glucose homeostasis and glucose tolerance in 
young (< 5 months) versus old mice (> 18 
months). We fasted mice over-night and 
measured their blood glucose the following 
morning. As shown in Figure 1, in young 
mice there was no significant difference be-
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tween the WT and AHR-KO mice. The mean 
fasted blood glucose level was 89.5 ± 14.6 
mg/dl for WT and 87.0 ± 18.6 mg/dl for 
AHR-KO mice, respectively. For young 
mice, which had not been fasted, the glucose 
levels were generally higher (141.3 ± 16.6 in 
WT vs. 129.3 ± 9.0 mg/dl in AHR-KO), but 
also not significantly different (data not 
shown). However, we observed a significant 
difference in old mice. AHR-KO mice had 
mean fasted blood glucose values of 108.2 
± 15.6 mg/dl and WT mice 78.7 ± 15.4 mg 
/dl. In other words, old AHR-KO mice had 
appr. 25 % higher glucose levels than old 
WT. Indeed, in old mice which had not been 
fasted over-night, the mean glucose level dif-
ference between AHR-KO and WT was even 
higher (156.6 ± 18.3 vs. 109.2 ± 12.1 mg/dl, 
data not shown).  
Interestingly, in fasted WT mice the 
blood glucose levels did not change with 
age, whereas in fasted AHR-KO mice the 
blood glucose levels were significantly high-
er in old than in young animals (p = 0.039). 
Also for mice, which had not been fasted, 
only the AHR-KO mice, but not the WT 
mice, had higher blood glucose levels in old 
versus young mice (data not shown). Taken 
together, the results demonstrate that old 
AHR-KO mice have higher blood glucose 
levels in comparison to old WT mice, and 
AHR-KO cannot maintain blood glucose 
homeostasis with age.  
To further assess the ability of AHR KO 
mice to maintain glucose homeostasis we 
performed a glucose tolerance test. Mice 
were injected with glucose i.p. and their 
blood glucose levels measured for up to two 
hours. The results for young and old mice 
are shown in Figure 2. Both strains and age 
groups were capable of down-regulating 
blood glucose levels to normal values within 
two hours. However, old AHR-KO mice dis-
played significantly greater difficulties in 
coping with the glucose challenge, i.e. their 
blood glucose concentrations initially 
 
Figure 1: Glucose levels in fasted young and 
old WT and AHR-KO mice 
WT (black bars) and AHR-KO (white bars) mice 
were fasted for 15 hours and then their blood 
glucose levels were measured. Mice were < 4 
months (young) or > 15 months (old) of age. 
Student´s t-test *** P < 0.001; * P < 0.05. N = 4 
(young mice) or 10-12 (old mice). Means +/- SD 
 
 
increased to higher levels, then returned 
more slowly to normal values than in WT 
mice. When calculated as area under the cure 
(AUC), values were 39 % higher in old 
AHR-KO than in old WT (Figure 2, insert).  
 
Insulin kinetics in WT and AHR-KO in 
glucose challenged mice 
To test whether the impaired glucose tol-
erance in AHR KO mice is caused by re-
duced insulin release we assessed the insulin 
secretory capacity of the animals. Insulin 
levels were determined during a glucose tol-
erance test (GTT) in WT versus AHR-KO 
mice (Figure 3). In young mice, we detected 
no difference between the insulin kinetics af-
ter glucose challenge (Figure 3A). In old 
mice, basal insulin levels were higher on av-
erage than in young mice, and insulin levels 
differed strongly between individuals. Insu-
lin levels increased in response to the glu-
cose challenge in both WT and AHR-KO 
lines, on average two-fold. Levels returned 
to basal values within the observation period. 
Histologically, there was no apparent differ-
ence in size and number of islets in the pan-
creas in either strain (data not shown). We 
did not observe different body weights be-
tween AHR-KO and WT mice (see Figure 4, 
insert). The average weight was 26.5 ± 2.5 g 
and 26.4 ± 1.5 for three months old WT and 
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AHR-KO, and 33.4 ± 3.9 and 33.7 ± 4.0 for 
two years old WT and AHR-KO, respective-
ly (N = 30 and 19). Similarly, there was no 
difference in the wet weight of epididymal 
fat tissue in young mice (data not shown). 
In aggregate, AHR-KO mice have an im-
paired capacity to quickly regulate blood 
glucose levels despite the ability to upregu-
late insulin release upon glucose challenge. 
This worsens with age and eventually old 
AHR-KO mice have higher blood glucose 
levels than WT mice.  
 
 
 
Figure 2: Kinetics of blood glucose levels in young and old mice after GTT 
C57BL/6 wildtype (black squares) and AHR-KO mice (white squares) were injected i.p with 2g glu-
cose/kg body weight and their blood glucose levels monitored for two hours at the indicated time 
points. (A) young mice (2-4 months) (B) old mice (18-24 months) Insert: Percent difference between 
the areas under the curve of WT versus AHR-KO for the young and old mice. Data shown are of two 
pooled independent experiments, N = 8 for young mice, N = 9 for old mice, each genotype. * P < 0.05; 
** P < 0.001 
 
 
Figure 3: Insulin levels in old mice after GTT 
C57BL/6 wildtype and AHR-KO mice were injected i.p. with 2g glucose/kg body weight and insulin 
levels were monitored for up to two hours at the indicated time points. AHR-KO (white squares), WT 
(black circles). Differences in insulin levels between WT and AHR-KO are not statistically significant. 
(A) young mice. (B) old mice.  
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Figure 4: Lipid profile of young WT and AHR-KO 
Serum lipid measurements of postprandial young WT and AHR-KO mice. TG: Triglycerides; Chol: 
cholesterol; HDL-C: High density lipoprotein; LDL-C: low density lipoprotein. N = 10 (WT, black bars) 
and 10 (AHR-KO, white bars), partly pooled for measurement. * P < 0.05 ***p < 0.0001; Insert: Body 
weight of young (1,2) and old (3,4) WT (black bars) or AHR-KO (white bars).  
 
 
Dyslipidemia in old and young WT and 
AHR-KO mice  
Besides dysregulated glucose homeosta-
sis, derangements of lipid metabolism, par-
ticularly increased triglycerides and LDL are 
major diabetes-promoting metabolic disor-
ders. We therefore measured TG, cholester-
ol, HDL-C, LDL-C and VLDL in the serum 
of young AHR-KO and WT mice, and of 18-
21 months old AHR-KO mice. As shown in 
Figure 4 and Table 1, we found that TG, 
cholesterol, HDL-C, and VLDL values were 
significantly lower in young AHR-KO mice 
compared to age-matched WT animals. LDL 
levels did not differ between the two geno-
types. There was no difference in any of 
these lipid marker between old and young 
mice; thus, there was no age associated 
change in the overall serum lipid markers. 
For TG this has been reported before (Traber 
et al., 2010). Aged AHR-KO were an excep-
tion, as they had slightly more cholesterol. 
The significantly lower values for cholester-
ol in young AHR-KO vs. young WT leveled 
out with age. Overall, values for young WT 
mice are similar to those reported in the lit-
erature and relevant databases (see 
http://www.phenome.jax.org). As expected, 
we found that fasted mice had lower values 
for TG. When we stratified data of the old 
mice for ´fasted versus post-prandial´, only 
LDL-C was different between fasted WT and 
AHR-KO (higher), all the other markers 
were similar between genotypes. AHR-KO 
mice were more resistant to post-prandial TG 
increase, and prone to post-prandial HDL-C 
decrease. Mice gained weight with age, but 
there was no difference between genotypes 
(see Fig HDL, insert). Also, epididymal adi-
pose tissue weight did not differ between 
AHR-KO and WT mice at 6 months of age 
(data not shown).  
 
DISCUSSION 
T2D is a major global concern because of 
the sheer number of people affected, the re-
lated severe health issues, and the high costs 
placed on health care systems. Notably, T2D 
develops with age, reflecting the involve-
ment of both environmental factors and an 
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Table 1: Lipids in seruma 
Lipids 
Age 
young old 
post-prandial fasted post-prandial fasted 
TG 
WT 140.3 ± 20.8 67.8 ± 15.7 123.0 ± 3.7 50.3 ± 6.2 
KO 84.4 ± 5.6* 109.0 ± 26.2** 82.1 ± 7.1* 56.1 ± 5.1 
Cholesterol 
WT 101.3 ± 4.6 97.3 ± 21.2 95.0 ± 6.2 90.6 ± 6.4 
KO 65.1 ± 2.2*** 94.8 ± 15.7 73.7 ± 7.1 120.3 ± 21.1 
HDL-C 
WT 72.1 ± 5.3 87.83 ± 2.8 78.0 ± 8.0 78.1 ± 4.0 
KO 45.3 ± 2.9*** 88.2 ± 14.5 52.8 ± 5.8* 89.4 ± 9.9 
LDL-C 
WT 15.0 ± 1.1 10.0 ± 1.67 12.8 ± 1.0 7.7 ± 1.0 
KO  13.9 ± 1.6 13.34 ± 1.2** 17.5 ± 4.8 16.1 ± 1.9** 
VLDL 
WT 12.8 ± 0.7 n.d. n.d. n.d. 
KO 6.7 ± 0.4*** n.d. n.d. n.d. 
a all values measured in serum as mg/dl 
“young” 3-7 months ; „old“ 18-24 months 
* = P < 0.05; ** = P < 0.001; *** P < 0.0001 WT versus AHR-KO; underlined: significantly different at least P < 0.05 between 
fasted and post-prandial; n.d. = not done  
 
 
adverse life-style. In addition individual ge-
netic factors might be relevant. Epidemiolo-
gical and laboratory studies have provided 
evidence that exposure to AHR agonists, in 
particular polycyclic aromatic hydrocarbons 
such as 2,3,7,8- TCDD, affects glucose ho-
meostasis and increases the incidence of 
T2D (Bock, 1994; Goodman et al., 2015; 
Warner et al., 2013). While early research on 
AHR has focused on toxic activation by pol-
ycyclic aromatic hydrocarbons, i.e., persis-
tent environmental pollutants, recent studies 
have highlighted important roles for AHR in 
normal development and physiology (Pas-
cussi et al., 2008; Swedenborg et al., 2009). 
It has long been known that AHR signaling 
can affect metabolism, including of glucose 
and lipids, and mitochondria function (Park 
et al., 2013). Nonetheless, few studies have 
looked at glucose homeostasis in AHR-
deficient mice, and none explicitly looked at 
older mice. We here report dyslipidemia and 
dysbalanced glucose homeostasis in AHR-
KO mice. Both parameters are known to 
contribute to the development of T2D in 
humans. 
We detected an impaired glucose toler-
ance in old AHR-KO mice. An independent 
study of Thackaberry et al. (2003) reported 
no difference in oral glucose tolerance (GT) 
in pregnant mice, but a somewhat higher oral 
GT in non-pregnant young female mice, and 
overt GT in 23 % of seven months old fe-
male AHR-deficient mice. The authors sug-
gested that glucose intolerance is an age ef-
fect. Our data on much older mice confirm 
and extend this idea. The Thackaberry group 
reported decreased serum insulin levels in 
their seven months old female mice. In an-
other study, the group of S. Tischkau report-
ed improved oral GT in young mice (mixed 
male and female) (Wang et al., 2011). We 
currently have no explanation for these con-
trasting results, but note that basal fasting 
glucose was higher as well in their study. It 
is unclear whether this is due to a sex-
specific effect or the much higher age in our 
study. It will be important to analyze further 
possibly influencing factors such as sex, 
stress, housing conditions, specific chow, or 
the inadvertent possibility of genetic drift in 
mouse lines of various laboratories (Phillips 
et al., 1999).  
EXCLI Journal 2015;14:1153-1163 – ISSN 1611-2156 
Received: October 22, 2015, accepted: November 02, 2015, published: November 18, 2015 
 
 
1160 
Lipids are transported in blood com-
plexed with many proteins, which collective-
ly are called HDL or LDL. Cholesterol and 
TG are complexed within LDL, and high 
levels of LDL are risk factors for atheroscle-
rosis and cardiovascular disease. The mouse 
lipoproteom resembles closely the human 
situation, and the mouse is a relevant model 
to study questions associated with, e.g., HDL 
levels (Gordon et al., 2015). Increased TG 
and LDL, together with lower HDL establish 
an “atherogenic lipid profile”, which may be 
associated with cardiovascular risk. As 
shown in Figure 4 for young mice, we found 
that TG levels in postprandial AHR-KO, ra-
ther than being increased, were significantly 
lower than in wildtype. However, consistent 
with an atherogenic profile and symptoms of 
the so-called metabolic syndrome, HDL lev-
els were significantly lower in AHR-KO. 
LDL did not differ between the two geno-
types. VLDL was significantly lower in se-
rum of AHR-KO mice than in wildtype lit-
termates. Unexpectedly, there was no differ-
ence in any of these lipid markers between 
old and young AHR-KO, thus there was no 
age associated change in the AHR-KO mice 
with respect to these parameters. The expres-
sion of the enzyme LpL (lipoprotein lipase) 
increases with age in the livers of both WT 
and AHR-KO mice, and was reportedly 
higher in 60-week old AHR-KO than WT 
mice (Minami et al., 2008). Lpl is the en-
zyme which dissolves lipoproteins and thus 
can release TG. It is known that AHR activa-
tion can induce steatosis, and an accumula-
tion of TG (Lee et al., 2010). Moreover, Lpl 
has a putative DRE in its promoter (Sun et 
al., 2004) and might thus need AHR for con-
stitutive expression; together this might ex-
plain the low TG levels in AHR-KO mice. 
Curiously, we did not find obesity associated 
with AHR-deficiency in mice. This is con-
gruent with data from other groups and a 
second AHR-KO strain as well (Sato et al., 
2008; Xu et al., 2015). Physical activity is a 
major factor in developing metabolic syn-
drome. A recent study suggested that a low 
affinity AHR allele leads to higher activity 
(Williams et al., 2014). Indeed, considering 
that AHR is part of a gene-network in hu-
mans responsive to physical activity, such an 
influence is possible (Phillips et al., 2013). 
Moreover, recent data shows that AHR is in-
volved in energy expenditure in experimen-
tally induced obesity as well (Xu et al., 
2015). Thus a highly complex picture 
emerges, where AHR has positive impact in 
some ways, but is not beneficial in other me-
tabolism related aspects.  
Our data suggest that AHR-deficiency 
will in the long run be detrimental to me-
tabolism. AHR-mediated gene regulation, 
which has been reported for hundreds of 
genes (Sun et al., 2004) in young mice, will 
conceivably differ in old mice, and more re-
search is needed to identify geriatric gene 
regulation and the environmental parameters 
which might shape it.  
Removal of AHR ligands from the diet of 
mice can result in similar symptoms as ge-
netic AHR deficiency. This has been shown 
in studies looking at gut barrier, immune cell 
development and infection susceptibility 
(Kiss et al., 2011; Li et al., 2011). It has 
therefore been suggested, that the diet will 
have major influences on “healthy” AHR 
signaling, which needs to be not too low, and 
not too high/persistent (as evident from the 
data with TCDD and other xenobiotic AHR-
ligands). A host of epidemiological studies 
has cemented the beneficial effects of certain 
diets, especially diets rich in vegetables 
(Calton et al., 2014). Our data are very well 
congruent with this, and suggest a causal 
molecular mechanism, which was previously 
overlooked.  
In conclusion, or data highlight involve-
ment of AHR in glucose and lipid metabo-
lism. As AHR-ligand withdrawal in the diet 
can mimic the outcome of AHR-deficiency 
in mice, proper consideration must be given 
to the potential risk of chronic AHR-ligand 
low (i.e. too few vegetables) diets which do 
not support the AHR signaling system in a 
physiological way.  
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